Research review shows intermittent fasting works for weight loss, health changes

Intermittent fasting can produce clinically significant weight loss as well as improve metabolic health in individuals with obesity, according to a new study review led by University of Illinois Chicago researchers. 

“We noted that intermittent fasting is not better than regular dieting; both produce the same amount of weight loss and similar changes in blood pressure, cholesterol and inflammation,” said Krista Varady, professor of nutrition at the UIC College of Applied Health Sciences and author of “Cardiometabolic Benefits of Intermittent Fasting.” 

According to the analysis published in the Annual Review of Nutrition, all forms of fasting reviewed produced mild to moderate weight loss, 1%-8% from baseline weight, which represents results that are similar to that of more traditional, calorie-restrictive diets. Intermittent fasting regimens may also benefit health by decreasing blood pressure and insulin resistance, and in some cases, cholesterol and triglyceride levels are also lowered. Other health benefits, such as improved appetite regulation and positive changes in the gut microbiome, have also been demonstrated. 

The review looked at over 25 research studies involving three types of intermittent fasting: 

  • Alternate day fasting, which typically involves a feast day alternated with a fast day where 500 calories are consumed in one meal. 
  • 5:2 diet, a modified version of alternate day fasting that involves five feast days and two fast days per week. 
  • Time-restricted eating, which confines eating to a specified number of hours per day, usually four to 10 hours, with no calorie restrictions during the eating period. 

Various studies of time-restricted eating show participants with obesity losing an average of 3% of their body weight, regardless of the time of the eating window. 

Studies showed alternate day fasting resulted in weight loss of 3%-8% of body weight over three to eight weeks, with results peaking at 12 weeks. Individuals on alternate day fasting typically do not overeat or binge on feast days, which results in mild to moderate weight loss, according to the review. 

Studies for the 5:2 diet showed similar results to alternate day fasting, which surprised the study’s reviewers. The subjects who participate in the 5:2 diet fast much less frequently than alternate-day fasting participants do, but the results of weight loss results are similar.  

Weight loss in both the alternate day and 5:2 fasting are comparable to more traditional daily calorie-restrictive diets. And, both fasting diets showed individuals were able to maintain an average of 7% weight loss for a year. 

“You’re fooling your body into eating a little bit less and that’s why people are losing weight,” Varady said. 

Varady added the review set out to debunk some myths regarding intermittent fasting. Intermittent fasting does not negatively affect metabolism, nor does it cause disordered eating, according to the studies reviewed.  

“Fasting people are worried about feeling lethargic and not being able to concentrate. Even though you are not eating, it won’t affect your energy,” Varady said. “A lot of people experience a boost of energy on fasting days. Don’t worry, you won’t feel crappy. You may even feel better.” 

The study review includes a summary of practical considerations for those who may want to try intermittent fasting. Among the considerations are: 

  • Adjustment time — Side effects such as headaches, dizziness and constipation subside after one to two weeks of fasting. Increased water intake can help alleviate headaches caused by dehydration during this time. 
  • Exercise — Moderate to high-intensity endurance or resistance training during food abstention can be done, and some study participants reported having more energy on fast days. However, studies recommend those following alternate day fasting eat their fasting day meal after exercise. 
  • Diet during fasting — There are no specific recommendations for food consumption during intermittent fasting, but eating fruits, vegetables and whole grains can help boost fiber intake and help relieve constipation that sometimes accompanies fasting. 
  • Alcohol and caffeine — For those using an alternate day or 5:2 fasting plan, alcohol is not recommended on fast days as the limited calories should be used on healthy foods that provide nutrition. 

There are several groups who should not intermittent fast, according to the studies. Those individuals include: 

  • Those who are pregnant or lactating. 
  • Children under 12. 
  • Those with a history of disordered eating. 
  • Those with a body mass index, or BMI, less than 18.5.
  • Shift workers. Studies have shown they may struggle with fasting regimens because of shifting work schedules. 
  • Those who need to take medication with food at regimented times. 

“People love intermittent fasting because it’s easy. People need to find diets that they can stick to long term. It’s definitely effective for weight loss and it’s gained popularity because there are no special foods or apps necessary. You can also combine it with other diets, like Keto,” Varady said. 

Intermittent fasting ‘no magic bullet for weight loss’ says new study

New research published this week challenges a popular belief that intermittent fasting diets such as alternate day fasting or the ‘5:2’ are the most effective ways to lose weight.

Over recent years, diets which see people fast on a few days each week have increased in popularity, reinforced by images of people’s miraculous weight transformations, and backed by celebrity endorsements.

However, evidence to date about the effectiveness of fasting compared with more traditional diets which aim to reduce calorie intake over the course of a full week has been limited.

Published in the prestigious journal Science Translational Medicine, the new study from a team of physiologists at the University of Bath builds this evidence and indicates that there is ‘nothing special’ about fasting.

Participants in their randomised control trial lost less weight when fasting in comparison with those following a traditional diet – even when their calorie intake was the same overall.

The trial, organised by a team from the University’s Centre for Nutrition, Exercise & Metabolism (CNEM), saw participants allocated into one of three groups:

  • Group 1 which fasted on alternate days with their fast day followed by a day of eating 50% more than usual.
  • Group 2 which reduced calories across all meals everyday by 25%.
  • Group 3 which fasted on alternate days (in the same way as Group 1) but followed their fast day with one day eating 100% more than usual.

Participants across all three groups were consuming a typical diet of around 2000-2500 kcal per day on average at the start of the study. Over the course of the three-week monitoring period, the two energy restricted groups reduced this to be between 1500-2000 kcal on average. Whereas groups 1 and 2 reduced their calorie intake by the same amount in different ways, group 3’s diet saw them fast without reducing overall calories.

Their results found that the non-fasting dieting group (Group 2) lost 1.9 kg in just three weeks, and DEXA body scans revealed this weight loss was almost entirely due to a reduction in body fat content.

By contrast, the first fasting group (Group 1) who experienced the same reduced calorie intake by fasting on alternate days and eating 50% more on non-fasting days, lost almost as much body weight (1.6 kg) but only half this weight loss was from reduced body fat with the remainder from muscle mass.

Group 3, who fasted but increased their energy intake by 100% on non-fasting days, did not need to draw on their body’s fat stores for energy and therefore weight loss was negligible.

Professor James Betts, Director of the Centre for Nutrition, Exercise & Metabolism at the University of Bath who led the research explains: “Many people believe that diets based on fasting are especially effective for weight loss or that these diets have particular metabolic health benefits even if you don’t lose weight.

“But intermittent fasting is no magic bullet and the findings of our experiment suggest that there is nothing special about fasting when compared with more traditional, standard diets people might follow.

“Most significantly, if you are following a fasting diet it is worth thinking about whether prolonged fasting periods is actually making it harder to maintain muscle mass and physical activity levels, which are known to be very important factors for long-term health.”

These results focused on participants who were defined as ‘lean’ (i.e. body mass index 20-25 kg/m2). 36 people participated in the study which was conducted between 2018 – 2020 and funded by the University of Bath.

Weight-loss maintainers sit less than weight-stable people with obesity

Weight-loss maintainers sit less than weight-stable people with obesity
Weight-loss maintainers sit less than weight-stable people with obesity

People who are successful at weight-loss maintenance spend less time sitting during the week and weekends compared to weight-stable individuals with obesity, according to a paper published online in Obesity, The Obesity Society’s flagship journal. This is the first study to examine time spent in various sitting activities among weight-loss maintainers.

Prior findings from 2006 in the National Weight Control Registry indicated that weight-loss maintainers watched significantly less television than controls, but other sitting activities were not examined. In the current study, weight-loss maintainers did not significantly differ from controls in reported weekly sitting time spent watching television, but did differ in time spent in non-work-related time using a computer or video game.

Differences between the current study and National Weight Control Registry findings could reflect changes over the past 15 years in available electronic devices, including the rise in availability of computers and video games. Weight-loss maintainers and controls also did not appreciably differ in time spent sitting while reading or studying, traveling; or talking, texting and socializing. These could be considered more mentally active forms of sedentary behavior.

“The findings hopefully will prompt future weight maintenance intervention research testing the effects of and optimal approaches for reducing sedentary behavior, including non-work-related computer and video game usage. Future research should include objective measures of sedentary behavior and activity,” said Suzanne Phelan, Department of Kinesiology and Public Health and The Center for Health Research, California Polytechnic State University, in San Luis Obispo. Phelan is the corresponding author of the study.

Participants in the study included 4,305 weight-loss maintainers from WW (formerly Weight Watchers) who had maintained >9.1 kg of weight loss (24.7 kg on average) for 3.3 years and had an average current BMI of 27.6 kg/m2. The group of weight-stable individuals with obesity had an average BMI of 38.9 kg/m2. To gather data, the Multicontext Sitting Time and Paffenbarger physical activity questionnaires were administered.

Results revealed that weight-loss maintainers versus weight-stable individuals with obesity spent three hours less per day sitting during the week (10.9 versus 13.9) and weekends (9.7 versus 12.6). Weight-loss maintainers compared with controls also spent one hour less per day in non-work-related sitting using a computer or playing a video game during the week (1.4 versus 2.3) and weekends (1.5 versus 2.5). There were no meaningful differences between weight-loss maintainers and weight-stable individuals with obesity in the number of television sets and sedentary-promoting devices in the home (15.8 versus 14.8). Weight-loss maintainers expended significantly more calories per week in physical activity (1,835 versus 785).

“These findings are important for understanding behaviors that may enhance weight loss maintenance, and one of those may be to reduce sitting time and other modes of sedentary behavior. However, this study also showed that physical activity was associated with improved weight-loss maintenance. Thus, this study does not imply that simply standing more rather than sitting will contribute to weight-loss maintenance, but may suggest that less sitting that results in more movement is what is key to weight loss maintenance. Hence, sit less and move more,” said John M. Jakicic, PhD, FACSM, FTOS, Distinguished Professor, and Director of the Healthy Lifestyle Institute and the Physical Activity and Weight Management Research Center at the University of Pittsburgh in Pennsylvania. Jakicic was not associated with the research.

Other authors of the study include James Roake, Noemi Alarcon and Sarah Keadle of the Department of Kinesiology and Public Health and The Center for Health Research, California Polytechnic State University, in San Luis Obispo. Chad Rethorst of Texas A&M Agrilife in Dallas, Texas and Gary Foster of WW International, Inc. of New York and the Center for Weight and Eating Disorders, Perelman School of Medicine, University of Pennsylvania, in Philadelphia also co-authored the study.

Pairing bariatric procedure with diabetes drug increases weight loss

Bariatric surgery
Bariatric surgery

 Combining minimally invasive endoscopic sleeve gastroplasty (ESG) with the diabetes drug semaglutide can provide additional significant weight loss for patients who are not candidates for invasive weight-loss surgery, according to research that was selected for presentation at Digestive Disease Week® (DDW) 2021.

“As the worldwide obesity rate continues to climb, so do the number of people seeking bariatric surgery to treat their condition,” said Anna Carolina Hoff, MD, lead researcher on the study and founder and clinical director of Angioskope Brazil, São José dos Campos. “Surgical procedures are some of the most successful ways to help patients lose weight, but they can eventually come with complications. Our study shows that patients may not have to undergo invasive surgery to get similar results.”

In a double-blind study, researchers randomized 61 patients undergoing ESG into two groups with one group of 29 patients receiving semaglutide — an injectable glucagon-like peptide-1 receptor that has been known to stimulate weight loss — beginning one month after the procedure. Another group of 29 patients received a placebo administered with look-alike injector pens. Three patients were lost to follow-up. Participants were monitored each month for body weight and body composition, and blood panels were taken every three months.

Patients who received semaglutide lost on average 26.7 percent of their total body weight compared to the control group, which on average lost 19.6 percent of total body weight. The semaglutide group lost 86.3 percent of their excess weight — the amount of weight the patients needed to lose to reach normal BMI — compared to 60.4 percent for the control group. The semaglutide group also lost 12.7 percent of their body fat by weight compared to 9 percent for the control group. Finally, glycated hemoglobin (Hb1Ac) levels fell 0.95 for the semaglutide group and 0.61 for the controls.

Surgical procedures, such as laparoscopic sleeve gastrectomy, come with increased costs and a higher risk for complications, such as gastroesophageal reflux disease, or GERD. These surgical procedures are typically limited to those with a BMI of at least 35 with comorbidities, or with a BMI above 40. ESG can be performed at an earlier stage of the disease and at a lower BMI, so more patients can get the treatment they need before their disease progresses. Treating patients with obesity earlier can help reduce death and comorbidities as well as reduce costs associated with treatments for these conditions.

“ESG has been available to patients for years, but it has not always been as successful as surgical options in helping patients lose weight,” said Dr. Hoff. “We now have a minimally invasive procedure that can be just as successful when combined with semaglutide and can be made available to even more people looking to lose a significant amount of weight.”

ESG is performed by guiding a device through the patient’s throat and into the stomach, where an endoscopist uses sutures to make the stomach smaller. This helps patients lose weight by limiting the amount they can eat. Patients are candidates for ESG if they have a BMI at or above 30, and diet and exercise have not helped them lose weight, or if they are not a candidate for surgery, or do not wish to pursue surgery.

The researchers caution that long term durability of the treatment still needs to be determined.

DDW Presentation Details

Dr. Hoff will present data from the study, “Semaglutide in association to endoscopic sleeve gastroplasty: Taking endoscopic bariatric procedures outcomes to the next level,” abstract Su548, on Sunday, May 23, at 12:15 p.m. EDT. For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.ddw.org/press.

Weight loss drug hope for patients with type 2 diabetes

Easy-To-Follow Weight-Loss Guidelines for Men


Patients with type 2 diabetes that were treated with a weekly injection of the breakthrough drug Semaglutide were able to achieve an average weight loss of nearly 10kg, according to a new study published in The Lancet today.

Led by Melanie Davies, Professor of Diabetes Medicine at the University of Leicester and the Co-Director of the Leicester Diabetes Centre, the study showed that two thirds of patients with type 2 diabetes that were treated with weekly injections of a 2.4mg dose of Semaglutide were able to lose at least 5% of their body weight and achieved significant improvement in blood glucose control.

More than a quarter of patients were able to lose more than 15% of their body weight – far above that which has been observed with any other medicine administered to people with diabetes.

Professor Melanie Davies said:

“These results are exciting and represent a new era in weight management in people with type 2 diabetes – they mark a real paradigm shift in our ability to treat obesity, the results bring us closer to what we see with more invasive surgery.

“It is also really encouraging that along with the weight loss we saw real improvements in general health, with significant improvement in physical functioning scores, blood pressure and blood glucose control”.

This global multi-centre trial was conducted at 149 sites in 12 countries across North America, Europe, South America, the Middle East, South Africa and Asia, involving 1,210 patients with type 2 diabetes whose current treatment was not achieving sufficient blood sugar control, for instance through diet and exercise, or through the use of metformin and other glucose lowering medicines used to control the disease.

It is one of a portfolio of studies conducted as part of the Semaglutide Treatment Effect for people with obesity Programme (STEP) programme. Professor Davies has been involved in all four of the STEP clinical trials involving Semaglutide for weight management completed so far, where the medication was shown to help patients achieve an average weight of loss of between 10kg and 17kg of body weight.

Being overweight or obese is a significant contributor to type 2 diabetes. Many patients can manage their type 2 diabetes by eating a healthy diet, taking regular exercise, and using medications to help control blood sugar, or achieve glycemic control but for a significant minority of patients who have not seen much improvement in spite of these methods, semiglutide is a promising development.

The LDC has a world-renowned, multi-disciplinary research team, which is leading the way and providing the evidence behind the Leicester Diabetes Centre’s education programmes and widening the knowledge base for health and disease management.